Answers are grounded in this paper and cite their sources.
The human apoAI gene was expressed in E. coli by in-frame fusion to a modified beta-galactosidase gene present in plasmid pUR291. The fused beta-galactosidase-apoAI gene product was expressed at a high level and was recognized by an anti-human apoAI antiserum. Besides the fused protein, at least one degradation product having an Mr similar to that of beta-galactosidase was present in high amounts in bacterial extracts. These results and those of a pulse-chase experiment indicate that degradation took place only in the apoAI moiety of the chimeric protein.
No takes yet. Share an insight, caveat, or question.
Lorenzetti et al. (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: